Last 27 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Royalty Pharma plc's quarterly P/E stands at 22.6x, up 19.2% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 27.2% YoY to 15.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 29.76 | 22.63 | 19.32 | 13.16 | 128.68 | 18.98 | 13.57 | 5.85 | 28.66 | 759.25 | 6.38 | 42.41 | 15.37 |
| — | +19.2% | +42.4% | +125.2% | +348.9% | -97.5% | +112.5% | -86.2% | +86.5% | +6306.1% | — | +35.1% | +2.4% | |
| P/S Ratio | 9.65 | 10.64 | 8.69 | 8.10 | 8.75 | 7.92 | 6.33 | 7.43 | 7.32 | 7.99 | 7.09 | 7.61 | 8.65 |
| — | +34.3% | +37.4% | +9.1% | +19.5% | -0.9% | -10.8% | -2.3% | -15.3% | -0.1% | -22.3% | -28.5% | -27.3% | |
| P/B Ratio | 3.09 | 2.70 | 2.23 | 2.05 | 2.13 | 1.84 | 1.45 | 1.64 | 1.61 | 1.84 | 1.68 | 1.70 | 1.90 |
| — | +46.9% | +53.2% | +25.5% | +32.1% | -0.1% | -13.4% | -3.9% | -14.9% | -17.4% | -22.7% | -27.3% | -22.6% | |
| P/FCF | 9.22 | 8.82 | 6.54 | 7.02 | 13.92 | 7.55 | 5.06 | 5.96 | 5.98 | 6.83 | 5.47 | 7.11 | 7.66 |
| — | +16.9% | +29.2% | +17.9% | +132.8% | +10.6% | -7.5% | -16.2% | -22.0% | +29.0% | -39.6% | -37.2% | -31.0% | |
| EV / EBITDA | 20.01 | 15.64 | 19.22 | 16.20 | 43.36 | 12.30 | 13.56 | 6.71 | 22.16 | 146.66 | 7.38 | 31.99 | 14.80 |
| — | +27.2% | +41.7% | +141.4% | +95.6% | -91.6% | +83.9% | -79.0% | +49.8% | +1107.0% | — | +12.1% | +4.4% | |
| EV / EBIT | 20.06 | — | 16.64 | 13.25 | 43.36 | 12.30 | 13.56 | 6.71 | 22.16 | 146.66 | 7.38 | 31.99 | 14.80 |
| — | — | +22.7% | +97.5% | +95.6% | -91.6% | +83.9% | -79.0% | +49.8% | +1107.0% | — | +12.1% | +4.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Royalty Pharma plc's operating margin was 89.2% in Q1 2026, up 26.8 pp QoQ and down 4.8 pp YoY. The trailing four-quarter average of 64.5% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | 65.6% | 89.2% | 62.4% | 70.1% | 36.3% | 94.0% | 60.9% | 130.2% | 50.2% | -13.0% | 102.8% | 28.2% | 46.2% |
| — | -5.1% | +2.5% | -46.1% | -27.8% | +823.7% | -40.8% | +361.0% | +8.5% | -118.5% | +220.5% | -15.8% | -34.4% | |
| Net Margin | 32.4% | 46.8% | 34.4% | 47.3% | 5.2% | 41.9% | 35.1% | 96.3% | 19.0% | 0.8% | 82.9% | 13.4% | 42.3% |
| — | +11.5% | -1.8% | -50.9% | -72.5% | +4886.3% | -57.7% | +616.4% | -55.1% | -98.3% | +202.9% | -45.9% | -25.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.7% | 3.0% | 2.2% | 3.0% | 0.3% | 2.4% | 2.0% | 5.4% | 1.0% | 0.0% | 5.0% | 0.7% | 2.3% |
| — | +26.8% | +9.6% | -44.6% | -69.9% | +4843.6% | -59.8% | +631.3% | -55.1% | -98.6% | +209.9% | -45.7% | -21.8% | |
| ROA | 4.1% | 1.5% | 1.1% | 1.5% | 0.2% | 1.3% | 1.1% | 3.0% | 0.6% | 0.0% | 3.1% | 0.4% | 1.3% |
| — | +12.5% | -4.3% | -49.8% | -72.2% | +4425.2% | -62.6% | +596.8% | -54.6% | -98.5% | +216.0% | -45.7% | -23.2% | |
| ROIC | 6.7% | 2.3% | 1.6% | 1.9% | 0.9% | 2.4% | 1.6% | 3.4% | 1.3% | -0.4% | 3.0% | 0.8% | 1.3% |
| — | -3.3% | +2.2% | -45.3% | -27.9% | +771.0% | -47.0% | +341.2% | +4.8% | -114.9% | +230.9% | -14.8% | -31.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Royalty Pharma plc's Debt/EBITDA ratio is 15.9x, down from 23.0x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 70.8% YoY to 2.66x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.92 | 0.90 | 0.92 | 0.93 | 0.84 | 0.78 | 0.74 | 0.74 | 0.78 | 0.62 | 0.61 | 0.64 | 0.73 |
| — | +15.8% | +25.2% | +25.7% | +8.0% | +25.0% | +21.0% | +15.9% | +7.4% | -14.2% | -18.6% | -6.3% | +6.4% | |
| Debt / EBITDA | 5.73 | 15.91 | 22.98 | 20.93 | 50.23 | 15.27 | 19.03 | 8.72 | 31.23 | 153.64 | 8.02 | 36.47 | 17.89 |
| — | +4.1% | +20.8% | +140.1% | +60.8% | -90.1% | +137.2% | -76.1% | +74.6% | +1099.6% | — | +37.1% | +35.6% | |
| Current Ratio | 0.97 | 2.66 | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 |
| — | +70.8% | -32.3% | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | |
| Quick Ratio | 0.97 | 2.66 | 0.97 | 3.48 | 1.26 | 1.56 | 1.44 | 1.54 | 9.35 | 12.52 | 7.90 | 13.51 | 2.52 |
| — | +70.8% | -32.3% | +126.8% | -86.5% | -87.6% | -81.8% | -88.6% | +271.3% | +431.5% | +260.6% | +552.8% | -86.9% | |
| Interest Coverage | 5.30 | 5.99 | 4.78 | 6.58 | 2.32 | 7.64 | 6.08 | 13.12 | 4.97 | 0.90 | 16.19 | 3.65 | 8.48 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Deep dive into RPRX consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RPRX stock.
Royalty Pharma plc's current P/E is 29.8x. The average P/E over the last 4 quarters is 45.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Royalty Pharma plc's current operating margin is 65.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Royalty Pharma plc's business trajectory between earnings reports.